Rapid Communication Open Access
Copyright ©2006 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Oct 28, 2006; 12(40): 6515-6521
Published online Oct 28, 2006. doi: 10.3748/wjg.v12.i40.6515
Strong prognostic value of nodal and bone marrow micro-involvement in patients with pancreatic ductal carcinoma receiving no adjuvant chemotherapy
Emre F Yekebas, Dean Bogoevski, Björn-Christian Link, Jussuf T Kaifi, Robin Wachowiak, Oliver Mann, Asad Kutup, Guellue Cataldegirmen, Lars Wolfram, Jakob R Izbicki, Department of General, Visceral and Thoracic Surgery, University Medical Centre of Hamburg-Eppendorf, Hamburg, Germany
Michael Bubenheim, Institute of Medical Biometry and Epidemiology, University Medical Centre of Hamburg-Eppendorf, Hamburg, Germany
Andreas Erbersdobler, Institute of Pathology, University Medical Centre of Hamburg-Eppendorf, Hamburg, Germany
Klaus Pantel, Institute of Tumor Biology, University Medical Centre of Hamburg-Eppendorf, Hamburg, Germany
Christoph Klein, Institute of Immunology, University of Munich, Munich, Germany
Supported by the “Hamburger Krebsgesellschaft e. V.”(06-04-2004) , the Roggenbuck-Stiftung, Hamburg (05-07-2004), and the Deutsche Forschungsgemeinschaft, Bonn, Germany
Correspondence to: Jakob R Izbicki, MD, FACS, Department of General, Visceral and Thoracic Surgery, University Medical Centre of Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany. izbicki@uke.uni-hamburg.de
Telephone: +49-40-428032401 Fax: +49-40-4280344319
Received: April 18, 2006
Revised: August 12, 2006
Accepted: September 13, 2006
Published online: October 28, 2006


AIM: To study the prognostic value of adjuvant chemo-therapy in patients with pancreatic, ductal adenocar-cinoma.

METHODS: Lymph nodes from 106 patients with resectable pancreatic ductal adenocarcinoma were systematically sampled. A total of 318 lymph nodes classified histopathologically as tumor-free were examined using sensitive immunohistochemical assays. Forty-three (41%) of the 106 patients were staged as pT1/2, 63 (59%) as pT3/4, 51 (48%) as pN0, and 55 (52%) as pN1. The study population included 59 (56%) patients exhibiting G1/2, and 47 (44%) patients with G3 tumors. Patients received no adjuvant chemo- or radiation therapy and were followed up for a median of 12 (range: 3.5 to 139) mo.

RESULTS: Immunostaining with Ber-EP4 revealed nodal microinvolvement in lymph nodes classified as “tumor free” by conventional histopathology in 73 (69%) out of the 106 patients. Twenty-nine (57%) of 51 patients staged histopathologically as pN0 had nodal microinvolvement. The five-year survival probability for pN0-patients was 54% for those without nodal microinvolvement and 0% for those with nodal microinvolvement. Cox-regression modeling revealed the independent prognostic effect of nodal microinvolvement on recurrence-free (relative risk 2.92, P = 0.005) and overall (relative risk 2.49, P = 0.009) survival.

CONCLUSION: The study reveals strong and independent prognostic significance of nodal microinvolvement in patients with pancreatic ductal adenocarcinoma who have received no adjuvant therapy. The addition of immunohistochemical findings to histopathology reports may help to improve risk stratification of patients with pancreatic cancer.

Key Words: Pancreatic ductal adenocarcinoma, Nodal microinvolvement, Micrometastases


Pancreatic adenocarcinoma is the fifth leading cause of death among all malignancies[1], leading to approximately 40 000 deaths each year in Europe[2]. Reported probabilities of five-year survival after curative surgery are still below 10 percent[3]. Stage, grade and resection margin status are currently accepted as the most accurate pathologic variables predicting survival[4-10]. Pathologic staging only insufficiently reflects the individual risk to develop tumor recurrence which is even high in early tumor stages. Thus, effort continues to identify new prognosticators of tumor relapse that indicate the need of adjuvant therapy.

Occult residual tumor disease is suggested when either bone marrow or lymph nodes from which tumor relapse may originate are affected by micrometastatic lesions undetectable by conventional histopathology[11]. The clinical significance of antibodies against tumor-associated targets both in lymph nodes[12-15] and in bone marrow[15,16] is still controversial[16-26]. Various monoclonal antibodies are in use for micrometastatic detection, thus contributing to the incongruity of data and validity of results. These assays have been rarely used in patients with pancreatic carcinoma[27-31]. Recently, our group showed that immunohistochemical staining with the monoclonal antibody Ber-EP4 is a sensitive and specific method for detecting isolated or clusters of tumor cells in lymph nodes from patients with lung[13], esophageal[25], or pancreatic carcinomas[28]. Ber-EP4 is an antibody against two glycopolypeptides of 34 and 49 kD on the surface and in the cytoplasm of all epithelial cells (except parietal cells, hepatocytes, and the superficial layers of squamous epithelium).

The present study was to increase our knowledge gained in the previous studies on lymph node micrometastasis[25,28,31,32]. In non-small cell lung carcinoma[32], the risk to develop tumor relapse in pN1 patients is overall greater than in pN0 patients. However, we have shown that further risk stratification for patients with histopathological involvement may be performed according to their immunohistochemical status. Therefore, here we have extended our previously published study on lymph node-negative patients with pancreatic cancer[31] with patients staged as pN1 through conventional histology as well as the bone marrow data from those patients that gave us written consent. The primary aim of this study was to assess the role of immunohistochemically detectable micrometastases in lymph nodes of an unselected group of patients with “curatively” resected pancreatic ductal adenocarcinoma. The secondary aim was to assess whether lymph node microinvolvement is correlated to bone marrow micrometastasis and which of these two sites is a better indicator for tumor cell dissemination in pancreatic cancer.

Patients and study design

The local ethical committee of Hamburg approved this study. Informed consent was obtained from all patients before inclusion in the study. Tumor samples, lymph nodes, and bone marrow aspirates of the upper iliac crest were collected from 487 patients with pancreatic and periampullary malignancies. Out of these patients, 171 (35%) had carcinomas of the papilla of Vater, 47 (10%) exhibited carcinoma of the distal common bile duct, and 269 (55%) had pancreatic carcinoma. Out of these 269 patients, 49 (18%) had neuroendocrine tumors and 220 (82%) had true pancreatic carcinoma.

Our study population included 106 patients with resectable pancreatic ductal adenocarcinoma who had undergone curative surgery and had given informed consent for immunohistochemical analysis of lymph nodes. Patients with cystic malignancies (IPMN, cystadenocarcinoma), acinar cell and squamous cell carcinomas were not considered for this study. The most frequent surgical procedure was pancreatoduodenectomy. Lymph node dissection was performed as previously described by Pedrazzoli et al[33]. A total of 1643 lymph nodes were removed with a median number of 16 (range 7 to 38) lymph nodes per patient. Among all histopathologically negative lymph nodes, 318 were selected in a representative fashion as described most recently for subsequent immunohistochemical screening[31]. Tumor stage and grade were classified according to the 6th edition of the tumor-node-metastasis classification (TNM) of the International Union against Cancer[34] by investigators unaware of the immunohistochemical findings.

Follow-up evaluations at three-month intervals included a physical examination, abdominal ultrasonography, computed tomography of the abdomen and studies of tumor markers, i.e. carcinoembryonic antigen and CA 19-9. Out of all 106 patients studied, the vital status in 89 patients could be determined at the end of the study. Seventeen patients were excluded from the survival analysis because they were either censored or died within 90 d after surgery. From 3 patients, only information about the date of death but not of recurrence was available

Tissue preparation and immunohistochemical analysis

Lymph nodes were divided into two parts, one for conventional histopathology, the other was snap-frozen in liquid nitrogen within three hours after their removal and stored at -80°C until use. Only histopathologically “tumor-free” lymph nodes were screened by immunohistochemistry with the anti-epithelial-cell monoclonal antibody Ber-EP4 (IgG1; Dako, Hamburg, Germany) as described previously[14]. Ber-EP4 is an antibody against two glycopolypeptides of 34 and 49 kD on the surface and in the cytoplasm of all epithelial cells (except parietal cells, hepatocytes, and the superficial layers of squamous epithelium). The antibody does not react with mesenchymal tissue, including lymphoid tissue[15,23].

Cryostat sections (5 to 6 μm thick) were cut at three different levels in each node and transferred onto glass slides treated with 3-triethoxysilylpropylamin (Merck, Darmstadt, Germany). One section of the sample obtained at each level was stained by the alkaline phosphatase-antialkaline phosphatase technique combined with the new fuchsine stain (Sena, Heidelberg, Germany) for the visualization reaction[23].

In 16 control patients with nonepithelial tumors or inflammatory diseases, lymph nodes were consistently stained negative. Sections of normal colon served as positive staining controls and isotype-matched, irrelevant murine monoclonal antibodies served as negative controls (purified immunoglobulin mouse myeloma protein for IgG1; Sigma, Deisenhofen, Germany).

The slides were evaluated in a blinded fashion by two observers working independently (D.B., J.T.K.). Minimal tumor cell involvement in a lymph node that was considered to be tumor-free by conventional histopathological staining was defined as the presence of one to ten positive cells in the body of the node (Figure 1). If more than 10 cells were detected (2 lymph nodes in two patients), a HE re-staining was conducted. Under routine histology both lymph nodes were judged as negative.

Figure 1
Figure 1 Immunohistochemically detectable nodal microinvolvement with monoclonal antibody Ber EP4 (×400).

Aspirates of 4 to 8 mL of bone marrow from the iliac crest were obtained from those patients who gave additional written consent for sampling bone marrow (59 patients) and were processed as previously described[16]. The specimens were collected in heparin, and mononuclear cells isolated by density-gradient centrifugation through Ficoll-Hypaque (Pharmacia, Freiburg, Germany) at 400 r/min for 30 min, were deposited onto glass slides by cytocentrifugation at 150 r/min for 3 min. To detect tumor cells in bone marrow (Figure 2), we used the monoclonal antibody A45-B/B3 (IgG1; Micromet, Munich, Germany) that detects an epitope on a variety of cytokeratin components, including cytokeratins[14,15,18,20].

Figure 2
Figure 2 Immunohistochemically detectable bone marrow microinvolvement with monoclonal antibody AE1/AE3 (×400).
Statistical analysis

All statistical calculations concerning survival (overall and recurrence-free survival) were based on the group of 89 patients who were available for follow-up. The primary outcome measure was the five-year survival probability. Secondary outcomes were the incidence of local recurrence and distant metastases of the disease. Survival was calculated from the date of resection until the date of death from any cause. For patients lost to follow-up, data were censored on the date the patient was last seen alive. Associations between categorical variables were assessed using Fisher’s exact test. Survival estimates were derived using the method proposed by Kaplan and Meier[35] and the log-rank test was used to assess differences in survival estimates among the groups. Point and interval estimates of the survival probabilities at 60 mo were calculated. For comparison purposes, log-rank test and exact stratified log-rank test were performed. Cox proportional-hazards modeling[36] was used to investigate and adjust the major prognostic and stratification factors. P < 0.05 was considered statistically significant.

Since this analysis was intended to be explorative, no adjustment for multiple testing was carried out.

Characteristics of patients and comparison of staining procedures

One hundred and six patients [47 (44%) women and 59 (56%) men] with pancreatic ductal adenocarcinoma were included in the study. Their mean age was 61 years (range 32 to 83 years, median 61 years). Table 1 shows the characteristics of patients and tumors.

Table 1 Characteristics of patients and tumors.
VariablenBer-EP4 positive cellsin lymph nodes (n)
All patients10673
Primary Tumor
Carcinoma in situ10
Nodal status
Negative (pN0)5129*
Positive (pN1)5544*
Tumor Grade
Well differentiated (G1)54
Moderately differentiated (G2)5435
Poorly differentiated (G3)4734
Resection margin
Negative (R0)9059
Positive (R1)1614
Tumor cells in Bone marrow
Not analysed4733

A total of 318 lymph nodes classified to be “tumor-free” by conventional histopathology were analyzed. Positive cells in the sinuses, the lymphoid interstitium, or in both locations were found in 132 lymph nodes (42%). These 132 positive lymph nodes were found from 73 (69%) of the 106 patients by immunostaining. Whereas the presence of Ber-EP4 cells was significantly associated with nodal metastases (pN1) identified through conventional histopathology (P = 0.012), no correlation between tumor stage and tumor grade was found.


After an average observation period of 18 mo (range 3 to 137 mo, median 12 mo), the presence of nodal microinvolvement was associated with significantly reduced recurrence-free and overall survival probabilities. The Kaplan-Meyer overall survival curve for all patients who were stratified according to the presence or absence of occult tumor cells in lymph nodes showed a significant survival benefit for patients negative in immunohistochemistry (median not yet reached-NYR vs 13 mo; 2- year survival 66% vs 20%; 5-year survival 50% vs 0%) irrespective of the histopathological classification (pN0/pN1) of lymph nodes (log-rank test; P < 0.0001, Figure 3).

Figure 3
Figure 3 Overall survival according to the presence or absence of nodal microinvolvement in immunohistochemistry for patients alive at least 13 wk after surgery. Median: Not yet reached-NYR vs 13 mo; Mean: 81 (SD 15, 95% CI 52-109) vs 16 (SD 2, 95% CI 12-20); 2-yr overall survival 66% vs 20%; 5-yr overall survival 50% vs 0%.

The analysis of the subset of patients who were staged pN0 in conventional histopathology revealed significantly better survival rates in patients without occult tumor cells as compared with those with nodal microinvolvement (median NYR vs 17 mo; 2-year survival 70% vs 34%; 5-year survival 61% vs 0%; log-rank test; P=0.012, Figure 4). Patients without any nodal involvement, as excluded by both conventional histopathology and immunohistochemistry, had a five-year overall survival probability of 61% (standard error: 13%). In contrast, the five-year survival probability of pN0-patients with nodal microinvolvement resembled that of pN1-patients (log-rank test; P = 0.059, Figure 4) and in both groups no patient was still alive 5 years after surgery.

Figure 4
Figure 4 Overall survival according to the presence or absence of nodal metastases in conventional histopathology and immunohistochemistry for patients alive at least 13 wk after surgery. Median: Not yet reached-NYR vs 13 mo vs 10 mo; Mean: 90 (SD 15, 95% CI 60-119) vs 17 (SD 3, 95% CI 11-23) vs 14 (SD 2, 95% CI 7-13); 2-yr overall survival 66% vs 20%; 5-yr overall survival 50% vs 0%.

The predictive value of nodal microinvolvement was strengthened by the finding that pN1-patients who additionally had disseminated tumor cells in other lymph nodes classified as tumor-free by histopathology had shorter recurrence-free and overall survival probabilities than pN1-patients without occult tumor cells in immunohistochemistry (median survival 33 vs 10 mo; 2-year survival 69% vs 10%; 5-year survival 69% vs 0%; log rank test: P = 0.004 and P = 0.049, respectively, data not shown).

Although no statistical significance was reached, pN1-patients without nodal microinvolvement had better overall survival probabilities (median survival = 33 mo) than pN0-patients with nodal microinvolvement (median survival = 17 mo). This could in part confirm the hypothesis that nodal microinvolvement in patients not burdened with nodal metastases detected through routine histology (pN0) might literally reflect systemic disease, whereas pN1-patients without nodal microinvolvement could be in fact treated as locally advanced disease. This should be discussed very cautiously since only 8 patients were included in the group of pN1-patients without nodal microinvolvement, but all of them were alive at the last follow-up.

Influence of resection margins

A total of 16 patients among the entire study population had positive resection margins (R1-status), only 2 of them belonged to the subset of pN0-patients without nodal microinvolvement. The remaining 14 patients with positive resection margins were either staged pN1 or had nodal microinvolvement which was as reported above, per se associated with a significantly worse prognosis. Due to this distribution of patients with R1-status, log-rank test might not have the sufficient power to assess the influence of the resection margins on overall survival. Therefore, no significant differences were found between patients with positive resection margins, as compared with those with negative resection margins (P = 0.976, data not shown).

Influence of bone marrow micrometastases

Occult tumor cells were detected in 14 of 59 patients who were evaluated with respect to bone marrow micrometastases. No association was found between bone marrow and nodal microinvolvement (Fisher’s exact test, P = 0.75). Among the 14 patients with bone marrow micrometastases, 9 (64%) had also nodal microinvolvement, whereas 5 (36%) did not. In turn, Ber-EP4-positive cells in lymph nodes were detected in 31 (69%) of the 45 patients with negative bone marrow findings (Table 1). Neither bone marrow micrometastases nor nodal microinvolvement was found in 14 patients. Here, we want to stress the finding (although again not significant due to the small number of patients) that those patients without any nodal involvement (negative both in histopathology and IHC) who had bone marrow micrometastases seemed to have considerably worse overall prognosis (mean survival time: 8 mo) than patients without (mean survival time: 75 mo). This also has to be discussed with considerable caution since we identified only 3 patients with bone marrow micrometastases (without any nodal involvement), although they all died within the first year unlike the other 8 patients without bone marrow micrometastases who were all alive on the last follow-up.

As regards the influence of bone marrow micro-metastases alone, no significant differences were found with respect to relapse-free time (P = 0.55) and overall survival (P = 0.14), respectively. However, these results might be biased by the small number of patients analyzed.

Multivariate analysis

Apart from nodal involvement assessed either by histopathology or immunohistochemistry, the comparison of survival curves revealed also significant differences with respect to grading when G1,2 tumors were compared to G3 tumors (median survival time: 28 mo vs 12 mo; log-rank test: P < 0001).

Cox regression analysis identified the presence of occult tumor cells in lymph nodes, tumor grade, and histopathologically detectable lymph node involvement as independent prognostic factors for disease-free and overall survival (Table 2). With respect to 5-year recurrence-free time, nodal microinvolvement had a relative risk of 2.92 (95% confidence interval: 1.39 to 6.13; P = 0.005), as compared with negative findings in immunohistochemistry. G3 tumors had a relative risk of 3.14 as compared with G1/2 tumors (95% confidence interval: 1.74 to 5.68; P = 0.000) with respect to recurrence-free time. A pN1-stage, as compared to pN0 patients, carried a relative risk of 2.18 (95% confidence interval: 1.19 to 4.0; P = 0.012) as to overall survival time, but had no significant influence on recurrence-free time (relative risk of 1.66; 95% confidence interval: 0.89 to 3.10; P = 0.112). Age, sex and tumor stage had no independent prognostic influence on recurrence-free or overall survival.

Table 2 Cox regression analysis showing the presence of occult tumor cells in lymph nodes, tumor grade, and histopathologically detectable lymph node involvement as independent prognostic factors for disease-free and overall survival.
Prognostic factorReference groupRelative riskPLower bound
Upper bound
95% confidence interval
Recurrence-free (n = 86)
Age at surgery1.010.7060.981.03
GradeG I - GII3.140.0001.745.68
Nodal involvementpN01.660.1120.893.10
Nodal microinvolvement (Ber-EP4)Negative2.920.0051.396.13
Overall survival (n = 89)
Age at surgery1.000.9960.971.03
GradeG I - GII3.360.0001.905.94
Nodal involvementpN02.180.0121.194.00
Nodal microinvolvement (Ber-EP4)Negative2.490.0091.254.96

The analysis of the interaction between pN-status, nodal microinvolvement and grading did not reveal that the proportional assumption was violated. Hence, the Cox model appeared appropriate and grading followed by nodal microinvolvement remained the two most important prognostic variables also in the subset of pN0-patients.


The key finding of this investigation is that isolated tumor cells, detectable in lymph nodes by immunohistochemical analysis, are strong independent prognosticators in pancreatic ductal adenocarcinoma irrespective of the histopathological N-status. We analyzed patients who suffered from pancreatic ductal adenocarcinoma and did not receive any adjuvant chemoradiation or chemotherapy. Two subsets of patients could be identified and were classified as pN0 in conventional histopathology. One subset with a poor five-year survival probability of 0% which was close to that of patients with overt nodal involvement (pN1), the other subset had a much better prognosis with a five-year survival probability of over 50% without nodal microinvolvement, suggesting that immunohistochemistry can confirm the cardinal importance of occult tumor cells for the separation of the respective survival curves in pN0-patients.

Even in patients who were staged as pN1, the detection of occult tumor cells in “tumor-free” lymph nodes had prognostic significance. This finding is consistent with previous observations of our group showing that survival is significantly worsened in both esophageal[25] and non-small cell lung carcinoma[32] when histopathological pN1-status is accompanied with nodal microinvolvement. Basically, pN1-status in solid tumors is considered as a local disease which can be potentially cured with surgery, although it generally carries a higher risk of systemic dissemination than pN0-status. Therefore, the finding that pN1 patients with additional nodal microinvolvement in “tumor-free” lymph nodes apart from overt lymph node metastases had significantly shorter recurrence-free survival as compared with pN1-patients without occult tumor cells suggests that immunohistochemistry may help to identify different risk profiles in these patients.

The reliability of these immunohistochemical assays used so far for detection of nodal microinvolvement is questioned[16-26] and could be also hampered by a sampling error[25,37]. The sampling error might be influenced by the number of lymph nodes dissected during the course of pancreatoduodenectomy and assessed by immunohistochemistry, as well as the number of lymph node sections and the level of these sections within the lymph nodes. In our present study, the lymph node dissection was performed as previously described by Pedrazzoli et al[33]. A total of 1643 lymph nodes were removed with a median number of 16 (range 7 to 38) lymph nodes per patient. Thus, the first possible cause of a sampling error was diminished, considering the high median lymph node yield of 16 per patient. In another study (oesophagus carcinoma, not yet published) all lymph nodes dissected in the course of esophagectomy were immunohistochemically stained, unlike in this and some other previously published studies[25] where only 20% of all lymph nodes were stained, showing comparable results in terms of impact on overall and relapse- free survival. We also believe that 6 sections cut from 3 different levels of each lymph node are enough for proper access to the nodal microinvolvement. Analyzing more than 3 sections would not be routinely feasible, and the positive correlation between the result of our assay and clinical outcome indicates that examining 3 lymph node levels are sufficient. The results from this study are in the same line with those published earlier from our group[25], thus confirming that the random selection of lymph nodes for IHC is enough for access to the nodal microinvolvement.

The strong adverse influence of nodal microinvolve-ment on outcome was most likely the reason for the lack of prognostic significance of resection margins in this series. In the ESPAC-1 trial, the resection margin status ceased to be an independent, prognostic factor for overall survival when tumor grading and pN-status were co-variables in the regression modeling[38], suggesting that the unfavorable outcome linked with poorly differentiated tumors with nodal metastases can hardly be impaired by further adverse variables, e.g. R1-status. We therefore assume that the characteristics of patients with R1-status are considerably biased. This hypothesis is strengthened by our observation that out of the 16 patients with R1-status all except two had occult tumor cells in immunohisto-chemistry.

Our data also indicate primary dissemination of tumor cells into lymph nodes before blood-borne spread occurs, because only 22% of the patients with nodal microinvolvement had identifiable tumor cells in their bone marrow. The lack of a significant difference in recurrence-free time between patients with nodal microinvolvement alone and those with additional involvement of the bone marrow suggests that the key event in pancreatic cancer progression is the spread of tumor cells to the regional lymph nodes. Nodal microinvolvement seems to indicate a systemic disease in pancreatic carcinoma much more accurately than occult tumor cells in bone marrow. However, these results have to be interpreted cautiously because bone marrow findings may have been biased by the fact that only a subset of patients was analyzed. Therefore, the influence of bone marrow microinvolvement on the outcome of patients with pancreatic carcinoma needs to be clarified in future studies.

Although chemoradiation and/or chemotherapy for adjuvant treatment of pancreatic carcinoma may have severe side effects[39], in common clinical practice, it is in most instances applied irrespective of tumor stage. This reflects the distrust in the value of conventional tumor-staging nomenclature in terms of reliably predicting the risk of tumor relapse even in patients with early pancreatic cancer (T1, N0). Our data indicate that immunohistochemical assessment of lymph nodes can be used to refine the staging system for pancreatic ductal adenocarcinoma and might help us to identify patients who could not be cured by surgery alone and need adjuvant therapy. In turn, patients who are true node-negative both in histopathology and in immunohistochemistry have an excellent five-year survival probability of nearly 60%, even without chemotherapy. Whether this prognosis can be further improved by adjuvant therapy needs further study.


S- Editor Wang J L- Editor Wang XL E- Editor Liu WF

1.  Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin. 2001;51:15-36.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 2582]  [Cited by in F6Publishing: 2409]  [Article Influence: 104.7]  [Reference Citation Analysis (0)]
2.  Parkin DM, Muir CS. Cancer Incidence in Five Continents. Comparability and quality of data. IARC Sci Publ. 1992;120:45-173.  [PubMed]  [DOI]  [Cited in This Article: ]
3.  Kuhlmann KF, de Castro SM, Wesseling JG, ten Kate FJ, Offerhaus GJ, Busch OR, van Gulik TM, Obertop H, Gouma DJ. Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients. Eur J Cancer. 2004;40:549-558.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 217]  [Cited by in F6Publishing: 196]  [Article Influence: 9.8]  [Reference Citation Analysis (0)]
4.  Allison DC, Piantadosi S, Hruban RH, Dooley WC, Fishman EK, Yeo CJ, Lillemoe KD, Pitt HA, Lin P, Cameron JL. DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma. J Surg Oncol. 1998;67:151-159.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 1]  [Reference Citation Analysis (0)]
5.  Allema JH, Reinders ME, van Gulik TM, Koelemay MJ, Van Leeuwen DJ, de Wit LT, Gouma DJ, Obertop H. Prognostic factors for survival after pancreaticoduodenectomy for patients with carcinoma of the pancreatic head region. Cancer. 1995;75:2069-2076.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 4]  [Reference Citation Analysis (0)]
6.  Yeo CJ, Abrams RA, Grochow LB, Sohn TA, Ord SE, Hruban RH, Zahurak ML, Dooley WC, Coleman J, Sauter PK. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg. 1997;225:621-633; discussion 633-6.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 449]  [Cited by in F6Publishing: 437]  [Article Influence: 16.2]  [Reference Citation Analysis (0)]
7.  Nitecki SS, Sarr MG, Colby TV, van Heerden JA. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg. 1995;221:59-66.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 428]  [Cited by in F6Publishing: 453]  [Article Influence: 15.6]  [Reference Citation Analysis (0)]
8.  Mosca F, Giulianotti PC, Balestracci T, Di Candio G, Pietrabissa A, Sbrana F, Rossi G. Long-term survival in pancreatic cancer: pylorus-preserving versus Whipple pancreatoduodenectomy. Surgery. 1997;122:553-566.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 103]  [Cited by in F6Publishing: 106]  [Article Influence: 3.9]  [Reference Citation Analysis (0)]
9.  Trede M, Schwall G, Saeger HD. Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality. Ann Surg. 1990;211:447-458.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 783]  [Cited by in F6Publishing: 760]  [Article Influence: 22.4]  [Reference Citation Analysis (0)]
10.  Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg. 1993;165:68-72; discussion 72-73.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 548]  [Cited by in F6Publishing: 587]  [Article Influence: 18.9]  [Reference Citation Analysis (1)]
11.  Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer. 2004;4:448-456.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 954]  [Cited by in F6Publishing: 924]  [Article Influence: 46.2]  [Reference Citation Analysis (0)]
12.  Byrne J, Waldron R, McAvinchey D, Dervan P. The use of monoclonal antibodies for the histopathological detection of mammary axillary micrometastases. Eur J Surg Oncol. 1987;13:409-411.  [PubMed]  [DOI]  [Cited in This Article: ]
13.  Passlick B, Izbicki JR, Kubuschok B, Nathrath W, Thetter O, Pichlmeier U, Schweiberer L, Riethmüller G, Pantel K. Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small-cell lung cancer. J Clin Oncol. 1994;12:1827-1832.  [PubMed]  [DOI]  [Cited in This Article: ]
14.  Raymond WA, Leong AS. Immunoperoxidase staining in the detection of lymph node metastases in stage I breast cancer. Pathology. 1989;21:11-15.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 36]  [Cited by in F6Publishing: 38]  [Article Influence: 1.1]  [Reference Citation Analysis (0)]
15.  Latza U, Niedobitek G, Schwarting R, Nekarda H, Stein H. Ber-EP4: new monoclonal antibody which distinguishes epithelia from mesothelial. J Clin Pathol. 1990;43:213-219.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 298]  [Cited by in F6Publishing: 275]  [Article Influence: 8.1]  [Reference Citation Analysis (0)]
16.  Pantel K, Izbicki JR, Angstwurm M, Braun S, Passlick B, Karg O, Thetter O, Riethmüller G. Immunocytological detection of bone marrow micrometastasis in operable non-small cell lung cancer. Cancer Res. 1993;53:1027-1031.  [PubMed]  [DOI]  [Cited in This Article: ]
17.  Bussolati G, Gugliotta P, Morra I, Pietribiasi F, Berardengo E. The immunohistochemical detection of lymph node metastases from infiltrating lobular carcinoma of the breast. Br J Cancer. 1986;54:631-636.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 79]  [Cited by in F6Publishing: 80]  [Article Influence: 2.1]  [Reference Citation Analysis (0)]
18.  Chen ZL, Perez S, Holmes EC, Wang HJ, Coulson WF, Wen DR, Cochran AJ. Frequency and distribution of occult micrometastases in lymph nodes of patients with non-small-cell lung carcinoma. J Natl Cancer Inst. 1993;85:493-498.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 129]  [Cited by in F6Publishing: 133]  [Article Influence: 4.3]  [Reference Citation Analysis (0)]
19.  de Mascarel I, Bonichon F, Coindre JM, Trojani M. Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: reevaluation with longer follow-up. Br J Cancer. 1992;66:523-527.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 233]  [Cited by in F6Publishing: 236]  [Article Influence: 7.4]  [Reference Citation Analysis (0)]
20.  Martini N, Flehinger BJ, Zaman MB, Beattie EJ Jr. Results of resection in non-oat cell carcinoma of the lung with mediastinal lymph node metastases. Ann Surg. 1983;198:386-397.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 288]  [Cited by in F6Publishing: 303]  [Article Influence: 7.4]  [Reference Citation Analysis (0)]
21.  Casson AG, Rusch VW, Ginsberg RJ, Zankowicz N, Finley RJ. Lymph node mapping of esophageal cancer. Ann Thorac Surg. 1994;58:1569-1570.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 56]  [Cited by in F6Publishing: 57]  [Article Influence: 1.9]  [Reference Citation Analysis (0)]
22.  Momburg F, Moldenhauer G, Hämmerling GJ, Möller P. Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. Cancer Res. 1987;47:2883-2891.  [PubMed]  [DOI]  [Cited in This Article: ]
23.  Pantel K, Schlimok G, Angstwurm M, Weckermann D, Schmaus W, Gath H, Passlick B, Izbicki JR, Riethmuller G. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. J Hematother. 1994;3:165-173.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 212]  [Cited by in F6Publishing: 210]  [Article Influence: 7.0]  [Reference Citation Analysis (0)]
24.  Kasper M, Stosiek P, Typlt H, Karsten U. Histological evaluation of three new monoclonal anti-cytokeratin antibodies. 1. Normal tissues. Eur J Cancer Clin Oncol. 1987;23:137-147.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 75]  [Cited by in F6Publishing: 75]  [Article Influence: 2.0]  [Reference Citation Analysis (0)]
25.  Izbicki JR, Hosch SB, Pichlmeier U, Rehders A, Busch C, Niendorf A, Passlick B, Broelsch CE, Pantel K. Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N Engl J Med. 1997;337:1188-1194.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 277]  [Cited by in F6Publishing: 279]  [Article Influence: 10.3]  [Reference Citation Analysis (0)]
26.  Z'graggen K, Centeno BA, Fernandez-del Castillo C, Jimenez RE, Werner J, Warshaw AL. Biological implications of tumor cells in blood and bone marrow of pancreatic cancer patients. Surgery. 2001;129:537-546.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 71]  [Cited by in F6Publishing: 76]  [Article Influence: 3.3]  [Reference Citation Analysis (0)]
27.  Kanemitsu K, Hiraoka T, Tsuji T, Inoue K, Takamori H. Implication of micrometastases of lymph nodes in patients with extended operation for pancreatic cancer. Pancreas. 2003;26:315-321.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 19]  [Cited by in F6Publishing: 19]  [Article Influence: 0.9]  [Reference Citation Analysis (0)]
28.  Hosch SB, Knoefel WT, Metz S, Stoecklein N, Niendorf A, Broelsch CE, Izbicki JR. Early lymphatic tumor cell dissemination in pancreatic cancer: frequency and prognostic significance. Pancreas. 1997;15:154-159.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 59]  [Cited by in F6Publishing: 59]  [Article Influence: 2.2]  [Reference Citation Analysis (0)]
29.  Vogel I, Krüger U, Marxsen J, Soeth E, Kalthoff H, Henne-Bruns D, Kremer B, Juhl H. Disseminated tumor cells in pancreatic cancer patients detected by immunocytology: a new prognostic factor. Clin Cancer Res. 1999;5:593-599.  [PubMed]  [DOI]  [Cited in This Article: ]
30.  Milsmann C, Füzesi L, Werner C, Becker H, Horstmann O. [Significance of occult lymphatic tumor spread in pancreatic cancer]. Chirurg. 2005;76:1064-1072.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 8]  [Cited by in F6Publishing: 7]  [Article Influence: 0.4]  [Reference Citation Analysis (0)]
31.  Bogoevski D, Yekebas EF, Schurr P, Kaifi JT, Kutup A, Erbersdobler A, Pantel K, Izbicki JR. Mode of spread in the early phase of lymphatic metastasis in pancreatic ductal adenocarcinoma: prognostic significance of nodal microinvolvement. Ann Surg. 2004;240:993-1000; discussion 1000-1001.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 31]  [Cited by in F6Publishing: 36]  [Article Influence: 1.9]  [Reference Citation Analysis (0)]
32.  Kubuschok B, Passlick B, Izbicki JR, Thetter O, Pantel K. Disseminated tumor cells in lymph nodes as a determinant for survival in surgically resected non-small-cell lung cancer. J Clin Oncol. 1999;17:19-24.  [PubMed]  [DOI]  [Cited in This Article: ]
33.  Pedrazzoli S, Beger HG, Obertop H, Andrén-Sandberg A, Fernández-Cruz L, Henne-Bruns D, Lüttges J, Neoptolemos JP. A surgical and pathological based classification of resective treatment of pancreatic cancer. Summary of an international workshop on surgical procedures in pancreatic cancer. Dig Surg. 1999;16:337-345.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 102]  [Cited by in F6Publishing: 108]  [Article Influence: 4.5]  [Reference Citation Analysis (0)]
34.  Hermanek P, Sobin LH.  TNM classification of malignant tumors. 4th ed. New York: Springer 1992; .  [PubMed]  [DOI]  [Cited in This Article: ]
35.  Klein JP, Moeschberger ML.  SURVIVAL ANALYSIS Tech-niques for Censored and Truncated Data. New York: Springer 1997; .  [PubMed]  [DOI]  [Cited in This Article: ]
36.  Cox DR. Regression Models and Life Tables (with discussion). J R Statist Soc. 1972;34:187-220.  [PubMed]  [DOI]  [Cited in This Article: ]
37.  Knisely AS. Cryptic tumor cells in lymph nodes of patients with esophageal cancer. N Engl J Med. 1998;338:550.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 8]  [Cited by in F6Publishing: 7]  [Article Influence: 0.3]  [Reference Citation Analysis (0)]
38.  Neoptolemos JP, Stocken DD, Dunn JA, Almond J, Beger HG, Pederzoli P, Bassi C, Dervenis C, Fernandez-Cruz L, Lacaine F. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg. 2001;234:758-768.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 493]  [Cited by in F6Publishing: 504]  [Article Influence: 21.9]  [Reference Citation Analysis (0)]
39.  Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200-1210.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1945]  [Cited by in F6Publishing: 1813]  [Article Influence: 90.7]  [Reference Citation Analysis (0)]